Pre-Open Stock Movers 07/28: (KODK) (LUMO) (CVLT) Higher; (ALNA) (EDU) (TSLA) Lower (more...)

Today's Pre-Open Stock Movers:

Kodak (NYSE: KODK) 229% HIGHER; $765 million Defense Production Act loan for drug ingredient push.

Lumos Pharma, Inc. (NASDAQ: LUMO) 21.4% HIGHER; announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck (NYSE: MRK), known as MSD outside the United States and Canada.

Commvault Systems (NASDAQ: CVLT) 13.5% HIGHER; reported Q1 EPS of $0.51, $0.35 better than the analyst estimate of $0.16. Revenue for the quarter came in at $173 million versus the consensus estimate of $152.87 million.

Amkor Technology (NASDAQ: AMKR) 11.5% HIGHER; reported Q2 EPS of $0.23, $0.26 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.05 billion. Amkor Technology sees Q3 2020 EPS of $0.17-$0.35, versus the consensus of $0.13. Amkor Technology sees Q3 2020 revenue of $1.2-1.3 billion, versus the consensus of $1.16 billion.

Vocera Communications, Inc. (NYSE: VCRA) 10.2% HIGHER; reported Q2 EPS of $0.10, $0.16 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $47.3 million versus the consensus estimate of $40.04 million.

Comfort Systems USA (NYSE: FIX) 9.3% HIGHER; reported Q2 EPS of $1.08, $0.63 better than the analyst estimate of $0.45. Revenue for the quarter came in at $743.5 million versus the consensus estimate of $700.92 million.

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) 9.1% LOWER; entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 3,846,154 shares of common stock of the Company, at a price to the public of $1.30 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 30, 2020, subject to satisfaction of customary closing conditions.

Unity Biotechnology Inc (NASDAQ: UBX) 7.9% HIGHER; Roth Capital initiates coverage on with a Buy rating and a price target of $35.00.

resTORbio, Inc. (Nasdaq: TORC) 7.1% HIGHER; TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a collaboration with resTORbio, Inc. (Nasdaq: TORC). resTORbio is a clinical-stage biotechnology company developing innovative medicines that target the biology of aging to treat aging-related diseases.

Altimmune (NASDAQ: ALT) 6.1% HIGHER; JMP Securities initiates coverage on with a Market Outperform rating and a price target of $50.00.

BioNTech SE (Nasdaq: BNTX) 5.5% HIGHER; Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2.

New Oriental Education (NYSE: EDU) 4.4% LOWER; reported Q4 EPS of $0.30, $0.05 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $798.5 million versus the consensus estimate of $796.71 million.

Bausch Health Co. Inc. (NYSE: BHC) 4.3% HIGHER; Larry Robbins' Glenview Capital filed a 13D on Bausch Health Co. Inc. (NYSE: BHC), disclosing a 20,944,128 share stake, or 5.9%. The firm held 16,617,008 shares of Bausch Health at the end of March. Glenview said it acquired the Shares and Call Options for investment purposes. Glenview intend to consider, explore and/or develop plans and/or make proposals (whether preliminary or final) with respect to, among other things, the Issuer’s businesses, assets, operations, and strategy, including plans or proposals in which the Reporting Persons and their affiliates may participate. The Reporting Persons and their affiliates intend to communicate with the Issuer’s management and board of directors, other shareholders or third parties, service providers and financing sources regarding the Issuer in an effort to explore ways to strengthen the Issuer and enhance shareholder value.

Sherwin-Williams (NYSE: SHW) 3.9% HIGHER; reported Q2 EPS of $7.10, $1.25 better than the analyst estimate of $5.85. Revenue for the quarter came in at $4.6 billion versus the consensus estimate of $4.58 billion. Sherwin-Williams sees FY2020 EPS of $19.21-$20.71, versus the consensus of $20.52.

F5 Networks (NASDAQ: FFIV) 3.6% LOWER; reported Q3 EPS of $2.18, $0.15 better than the analyst estimate of $2.03. Revenue for the quarter came in at $586 million versus the consensus estimate of $572.44 million.

NXP Semiconductors (NASDAQ: NXPI) 3.1% LOWER; reported Q2 EPS of ($0.77), $1.61 worse than the analyst estimate of $0.84. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.81 billion. NXP Semiconductors sees Q3 2020 revenue of $1.9-2 billion, versus the consensus of $1.88 billion.

Shopify (NYSE: SHOP) 3% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $1,127.00.

Luxfer Holdings plc (NYSE: LXFR) 2.7% HIGHER; reported Q2 EPS of $0.17, $0.03 better than the analyst estimate of $0.14. Revenue for the quarter came in at $89.5 million versus the consensus estimate of $85.15 million.

Chiasma, Inc. (NASDAQ: CHMA) 2.7% HIGHER; announced 48-week, open-label efficacy and safety data from the Phase 3 CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) open-label extension (OLE) study of MYCAPSSA® (octreotide) capsules.

Crane Co. (NYSE: CR) 2.5% HIGHER; reported Q2 EPS of $0.64, $0.17 better than the analyst estimate of $0.47. Revenue for the quarter came in at $677.9 million versus the consensus estimate of $626.09 million.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) 2.4% LOWER; announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to purchase up to $30.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Tesla (NASDAQ: TSLA) 2.1% LOWER; Bernstein downgraded from Market Perform to Underperform, PT $900.00.

JBT Corp. (NYSE: JBT) 2% HIGHER; reported Q2 EPS of $1.01, $0.27 better than the analyst estimate of $0.74. Revenue for the quarter came in at $411.5 million versus the consensus estimate of $396.38 million.

Costamare (NYSE: CMRE) 2% HIGHER; reported Q2 EPS of $0.26, $0.05 better than the analyst estimate of $0.21. Revenue for the quarter came in at $118.94 million versus the consensus estimate of $120.41 million.

Intevac. (NASDAQ: IVAC) 2% HIGHER; reported Q2 EPS of $0.06, $0.18 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $28.8 million versus the consensus estimate of $17.4 million.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
• Bernstein on Tesla: 'Widespread deployment of FSD is 5 - 10 years away'